Sign in or create an account to add this stock to your watchlist.
About Idexx Laboratories (NASDAQ:IDXX)
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300
Debt
Debt-to-Equity Ratio-12.43
Current Ratio0.96
Quick Ratio0.72
Price-To-Earnings
Trailing P/E Ratio61.41
Forward P/E Ratio48.37
P/E Growth2.39
Sales & Book Value
Annual Sales$1.97 billion
Price / Sales8.88
Cash Flow$4.3353 per share
Price / Cash46.41
Book Value($0.62) per share
Price / Book-324.52
Profitability
EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Net Margins13.87%
Return on Equity-530.24%
Return on Assets19.39%
Miscellaneous
Employees7,600
Outstanding Shares86,860,000
Idexx Laboratories (NASDAQ:IDXX) Frequently Asked Questions
What is Idexx Laboratories' stock symbol?
Idexx Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How will Idexx Laboratories' stock buyback program work?
Idexx Laboratories declared that its board has approved a share repurchase program on Sunday, June 4th 2017, which allows the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company's board believes its shares are undervalued.
How were Idexx Laboratories' earnings last quarter?
Idexx Laboratories (NASDAQ:IDXX) issued its quarterly earnings results on Friday, May, 4th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.09. The firm had revenue of $537.60 million for the quarter, compared to analyst estimates of $525.14 million. Idexx Laboratories had a net margin of 13.87% and a negative return on equity of 530.24%. Idexx Laboratories's revenue was up 16.4% on a year-over-year basis. During the same period last year, the business earned $0.77 EPS. View Idexx Laboratories' Earnings History.
When is Idexx Laboratories' next earnings date?
What guidance has Idexx Laboratories issued on next quarter's earnings?
Idexx Laboratories updated its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share (EPS) guidance of $4.06-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.11. The company issued revenue guidance of +12-14% to ~$2.205-2.245 billion, compared to the consensus revenue estimate of $2.22 billion.
What price target have analysts set for IDXX?
6 equities research analysts have issued 1 year price targets for Idexx Laboratories' shares. Their forecasts range from $118.00 to $225.00. On average, they expect Idexx Laboratories' stock price to reach $198.1667 in the next year. View Analyst Ratings for Idexx Laboratories.
Who are some of Idexx Laboratories' key competitors?
Some companies that are related to Idexx Laboratories include Ipsen (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB) and Vermillion (VRML).
Who are Idexx Laboratories' key executives?
Idexx Laboratories' management team includes the folowing people:
- Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
- Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 56)
- Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 54)
- Mr. Jay Mazelsky, Exec. VP (Age 57)
Has Idexx Laboratories been receiving favorable news coverage?
News articles about IDXX stock have trended somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Idexx Laboratories earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news articles about the company an impact score of 47.37 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Idexx Laboratories' major shareholders?
Idexx Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.61%), Bamco Inc. NY (5.15%), Blair William & Co. IL (1.87%), Neuberger Berman Group LLC (1.86%), Northern Trust Corp (1.16%) and Old Mutual Global Investors UK Ltd. (1.08%). Company insiders that own Idexx Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for Idexx Laboratories.
Which institutional investors are selling Idexx Laboratories stock?
IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bamco Inc. NY, Blair William & Co. IL, Millennium Management LLC, Federated Investors Inc. PA, Natixis, American Century Companies Inc. and Old Mutual Global Investors UK Ltd.. Company insiders that have sold Idexx Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for Idexx Laboratories.
Which institutional investors are buying Idexx Laboratories stock?
IDXX stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, AGF Investments Inc., Prudential Financial Inc., OppenheimerFunds Inc., Westfield Capital Management Co. LP, Wells Fargo & Company MN, Select Equity Group L.P. and Chicago Capital LLC. Company insiders that have bought Idexx Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for Idexx Laboratories.
How do I buy shares of Idexx Laboratories?
Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Idexx Laboratories' stock price today?
One share of IDXX stock can currently be purchased for approximately $201.20.
How big of a company is Idexx Laboratories?
Idexx Laboratories has a market capitalization of $17.44 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. Idexx Laboratories employs 7,600 workers across the globe.
How can I contact Idexx Laboratories?
Idexx Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]
MarketBeat Community Rating for Idexx Laboratories (IDXX)
MarketBeat's community ratings are surveys of what our community members think about Idexx Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Idexx Laboratories (NASDAQ:IDXX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Idexx Laboratories in the last 12 months. Their average twelve-month price target is $198.1667, suggesting that the stock has a possible downside of 1.51%. The high price target for IDXX is $225.00 and the low price target for IDXX is $118.00. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 2.33 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $198.1667 | $190.6667 | $190.6667 | $171.60 |
| Price Target Upside: | 1.51% downside | 0.96% downside | 0.96% downside | 4.36% upside |
Idexx Laboratories (NASDAQ:IDXX) Consensus Price Target History
Idexx Laboratories (NASDAQ:IDXX) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Idexx Laboratories (NASDAQ:IDXX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Idexx Laboratories (NASDAQ IDXX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.56%
Institutional Ownership Percentage: 86.14%
Idexx Laboratories (NASDAQ IDXX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/10/2018 | William T End | Director | Sell | 9,470 | $208.36 | $1,973,169.20 | 31,786 |  |
| 2/28/2018 | Daniel M Junius | Director | Sell | 2,974 | $190.06 | $565,238.44 | 5,602 | |
| 2/22/2018 | William T End | Director | Sell | 4,000 | $184.48 | $737,920.00 | 41,256 | |
| 2/14/2018 | Lawrence D Kingsley | Director | Buy | 1,000 | $178.05 | $178,050.00 | 4,558 | |
| 2/8/2018 | Jonathan W Ayers | Chairman | Sell | 22,000 | $177.52 | $3,905,440.00 | 1,077,112 | |
| 2/7/2018 | Bruce L Claflin | Director | Buy | 1,000 | $179.58 | $179,580.00 | 1,000 | |
| 2/6/2018 | Jonathan W Ayers | Chairman | Sell | 36,000 | $179.28 | $6,454,080.00 | 1,077,112 | |
| 2/5/2018 | Brian P Mckeon | VP | Sell | 6,602 | $181.36 | $1,197,338.72 | 47,040 | |
| 1/11/2018 | Jonathan W Ayers | CEO | Sell | 2,160 | $167.03 | $360,784.80 | 1,077,112 | |
| 1/9/2018 | Jonathan W Ayers | CEO | Sell | 18,000 | $165.15 | $2,972,700.00 | 1,077,112 | |
| 11/30/2017 | Giovani Twigge | Insider | Sell | 2,000 | $156.07 | $312,140.00 | | |
| 11/16/2017 | Jonathan W Ayers | CEO | Sell | 18,000 | $153.61 | $2,764,980.00 | 1,064,573 | |
| 11/14/2017 | Jonathan W Ayers | CEO | Sell | 18,000 | $148.35 | $2,670,300.00 | 1,064,573 | |
| 11/7/2017 | Jonathan W Ayers | Chairman | Sell | 54,000 | $151.32 | $8,171,280.00 | 1,064,573 | |
| 11/3/2017 | Jonathan W Ayers | CEO | Sell | 18,000 | $153.75 | $2,767,500.00 | 1,064,573 | |
| 8/28/2017 | Jonathan W Ayers | Chairman | Sell | 13,000 | $150.79 | $1,960,270.00 | 1,044,034 | |
| 8/23/2017 | Rebecca M Henderson | Director | Sell | 5,156 | $153.29 | $790,363.24 | 17,274 | |
| 8/22/2017 | Rebecca M Henderson | Director | Sell | 2,578 | $152.86 | $394,073.08 | 17,274 | |
| 8/16/2017 | Jonathan W Ayers | Chairman | Sell | 58,000 | $155.00 | $8,990,000.00 | 1,043,034 | |
| 8/15/2017 | Jonathan W Ayers | CEO | Sell | 20,000 | $154.62 | $3,092,400.00 | 1,043,034 | |
| 8/14/2017 | Jonathan W Ayers | CEO | Sell | 18,000 | $154.91 | $2,788,380.00 | 1,043,034 | |
| 8/9/2017 | Jonathan W Ayers | Chairman | Sell | 17,000 | $154.54 | $2,627,180.00 | 1,039,034 | |
| 8/8/2017 | Jonathan W. Ayers | Chairman | Sell | 18,000 | $155.22 | $2,793,960.00 | | |
| 8/3/2017 | Lawrence D Kingsley | Director | Buy | 2,000 | $151.76 | $303,520.00 | 3,344 | |
| 5/31/2017 | Giovani Twigge | Insider | Sell | 2,572 | $166.90 | $429,266.80 | | |
| 5/30/2017 | Jonathan W Ayers | Chairman | Sell | 13,000 | $167.82 | $2,181,660.00 | 1,032,994 | |
| 5/22/2017 | William T End | Director | Sell | 5,000 | $162.55 | $812,750.00 | 45,256 | |
| 5/10/2017 | Jonathan W Ayers | Chairman | Sell | 27,000 | $162.69 | $4,392,630.00 | 1,024,994 | |
| 5/5/2017 | Jonathan W. Ayers | Chairman | Sell | 26,000 | $160.61 | $4,175,860.00 | | |
| 5/4/2017 | Rebecca M Henderson | Director | Sell | 1,700 | $159.95 | $271,915.00 | 21,552 | |
| 3/1/2017 | Lawrence D Kingsley | Director | Buy | 1,000 | $146.48 | $146,480.00 | 1,135 | |
| 2/22/2017 | Jonathan W Ayers | Chairman | Sell | 35,000 | $142.58 | $4,990,300.00 | 995,947 | |
| 2/8/2017 | Brian P Mckeon | VP | Sell | 9,924 | $141.64 | $1,405,635.36 | 45,235 | |
| 2/8/2017 | Daniel M Junius | Director | Sell | 3,000 | $141.75 | $425,250.00 | 5,495 | |
| 2/8/2017 | Jonathan W. Ayers | Chairman | Sell | 36,250 | $141.63 | $5,134,087.50 | | |
| 11/29/2016 | Jonathan W Ayers | Chairman | Sell | 27,424 | $119.77 | $3,284,572.48 | 1,001,043 | |
| 11/28/2016 | Jonathan W Ayers | CEO | Sell | 13,188 | $119.57 | $1,576,889.16 | 1,001,043 | |
| 11/23/2016 | Thomas Craig | Director | Sell | 8,500 | $120.06 | $1,020,510.00 | 32,783 | |
| 11/9/2016 | Jonathan W. Ayers | Chairman | Sell | 40,000 | $107.85 | $4,314,000.00 | | |
| 11/8/2016 | William T End | Director | Sell | 5,000 | $109.87 | $549,350.00 | 48,654 | |
| 8/25/2016 | Rebecca M Henderson | Director | Sell | 9,924 | $110.43 | $1,095,907.32 | 16,678 | |
| 8/15/2016 | Barry C Johnson | Director | Sell | 9,924 | $111.37 | $1,105,235.88 | 13,484 | |
| 8/8/2016 | Michael J. Phd Williams | Insider | Sell | 49,560 | $108.94 | $5,399,066.40 | | |
| 8/5/2016 | William T End | Director | Sell | 5,000 | $108.50 | $542,500.00 | 53,564 | |
| 8/4/2016 | Jonathan W. Ayers | Chairman | Sell | 60,000 | $107.69 | $6,461,400.00 | | |
| 5/5/2016 | William T End | Director | Sell | 4,924 | $85.87 | $422,823.88 | 63,578 | |
| 2/24/2016 | Michael J Phd Williams | EVP | Sell | 2,000 | $71.93 | $143,860.00 | 40,011 | |
| 2/9/2016 | Thomas Craig | Director | Sell | 2,054 | $69.52 | $142,794.08 | 22,298 | |
| 2/8/2016 | Brian P. Mckeon | CFO | Sell | 9,054 | $69.65 | $630,611.10 | 32,461 | |
| 11/30/2015 | Thomas Craig | Director | Sell | 7,000 | $70.28 | $491,960.00 | 22,048 | |
| 11/12/2015 | Rebecca M. Henderson | Director | Sell | 2,300 | $68.39 | $157,297.00 | 21,450 | |
| 8/31/2015 | Thomas Craig | Director | Sell | 800 | $71.77 | $57,416.00 | 21,793 | |
| 8/18/2015 | Michael J. Phd Williams | EVP | Sell | 6,586 | $78.34 | $515,947.24 | 39,654 | |
| 8/18/2015 | Thomas Craig | Director | Sell | 2,900 | $79.41 | $230,289.00 | 22,593 | |
| 8/17/2015 | Jonathan W Ayers | CEO | Sell | 14,799 | $78.45 | $1,160,981.55 | | |
| 5/18/2015 | William T End | Director | Sell | 3,527 | $134.51 | $474,416.77 | | |
| 3/10/2015 | William T End | Director | Sell | 3,500 | $150.89 | $528,115.00 | | |
| 3/4/2015 | Johnny D Powers | EVP | Sell | 6,168 | $158.49 | $977,566.32 | | |
| 2/17/2015 | Brian P Mckeon | CFO | Sell | 5,000 | $156.99 | $784,950.00 | | |
| 2/12/2015 | Jonathan W Ayers | CEO | Sell | 58,245 | $155.45 | $9,054,185.25 | | |
| 2/5/2015 | Rebecca M Henderson | Director | Sell | 2,934 | $156.27 | $458,496.18 | | |
| 2/4/2015 | Thomas Craig | Director | Sell | 2,200 | $157.02 | $345,444.00 | | |
| 1/14/2015 | Jonathan W Ayers | CEO | Sell | 28,512 | $157.68 | $4,495,772.16 | | |
| 12/3/2014 | Jonathan W Ayers | CEO | Sell | 29,000 | $148.49 | $4,306,210.00 | | |
| 11/13/2014 | Thomas Craig | Director | Sell | 5,000 | $152.45 | $762,250.00 | | |
| 11/5/2014 | Jonathan W Ayers | CEO | Sell | 29,000 | $143.45 | $4,160,050.00 | | |
| 11/4/2014 | Johnny D Powers | EVP | Sell | 1,292 | $142.70 | $184,368.40 | | |
| 8/13/2014 | M Anne Szostak | Director | Buy | 2,000 | $127.03 | $254,060.00 | | |
| 2/20/2014 | M Anne Szostak | Director | Buy | 2,000 | $126.71 | $253,420.00 | 5,000 | |
| 2/19/2014 | Thomas Craig | Director | Sell | 4,800 | $125.42 | $602,016.00 | 11,976 | |
| 2/3/2014 | Jonathan Ayers | CEO | Sell | 81,294 | $112.46 | $9,142,323.24 | 389,665 | |
| 11/26/2013 | Jonathan Ayers | CEO | Sell | 78,178 | $105.29 | $8,231,361.62 | 377,211 | |
| 11/22/2013 | Sophie Vandebroek | Director | Buy | 1,000 | $107.84 | $107,840.00 | 1,000 | |
| 11/13/2013 | Jonathan Ayers | CEO | Sell | 78,178 | $106.36 | $8,315,012.08 | 365,389 | |
| 11/4/2013 | M Anne Szostak | Director | Buy | 1,000 | $108.24 | $108,240.00 | 3,000 | |
| 11/4/2013 | Michael Phd Williams | EVP | Sell | 6,020 | $108.19 | $651,303.80 | 11,566 | |
| 10/31/2013 | William T End | Director | Sell | 2,500 | $108.32 | $270,800.00 | | |
| 10/25/2013 | Jonathan W Ayers | CEO | Sell | 78,178 | $104.36 | $8,158,656.08 | | |
| 9/13/2013 | Johnny Powers | EVP | Sell | 13,128 | $96.59 | $1,268,033.52 | 8,989 | |
| 9/5/2013 | Michael J Phd Williams | EVP | Sell | 5,162 | $95.58 | $493,383.96 | | |
| 5/9/2013 | Ali Naqui | VP | Sell | 12,961 | $87.00 | $1,127,607.00 | | |
| 2/4/2013 | Merilee Raines | CFO | Sell | 175,929 | $94.25 | $16,581,308.25 | | |
| 11/13/2012 | Jonathan W Ayers | CEO | Sell | 15,000 | $89.92 | $1,348,800.00 | | |
| 9/5/2012 | Johnny D Powers | EVP | Sell | 4,000 | $97.12 | $388,480.00 | | |
| 8/8/2012 | Merilee Raines | CFO | Sell | 7,726 | $88.84 | $686,377.84 | | |
(Data available from 1/1/2013 forward)
Idexx Laboratories (NASDAQ IDXX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Idexx Laboratories (IDXX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 21 at 1:47 PM |
| Zacks: Brokerages Expect Idexx Laboratories (IDXX) Will Post Quarterly Sales of $574.95 Million
www.americanbankingnews.com - May 20 at 2:28 AM |
 | IDEXX: This Medical Equipment Stock Is Overvalued And Could Go Down As Much As 20%
seekingalpha.com - May 19 at 8:03 AM |
| Zacks: Analysts Anticipate Idexx Laboratories (IDXX) Will Post Earnings of $1.18 Per Share
www.americanbankingnews.com - May 18 at 7:35 PM |
| Idexx Laboratories (IDXX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 18 at 4:45 PM |
 | After the Bell: Dow Gains 63 Because Higher Bond Yields Don't Matter After All
finance.yahoo.com - May 17 at 8:08 AM |
 | BRIEF-IDEXX Laboratories says Reduced Board Size To Eight
www.reuters.com - May 16 at 8:05 AM |
| Critical Review: Idexx Laboratories (IDXX) & Trinity Biotech (TRIB)
www.americanbankingnews.com - May 12 at 11:33 AM |
| Idexx Laboratories (IDXX) Director Sells $1,973,169.20 in Stock
www.americanbankingnews.com - May 11 at 7:25 PM |
| IDEXX Laboratories Barks Out Another Successful Quarter
finance.yahoo.com - May 11 at 6:15 PM |
| Idexx Laboratories (IDXX) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - May 10 at 12:37 AM |
 | UPDATE: IDEXX Laboratories (IDXX) PT Raised to $225 at Stifel
www.streetinsider.com - May 8 at 8:05 AM |
 | IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?
www.nasdaq.com - May 7 at 5:49 PM |
| Idexx Laboratories (IDXX) Price Target Increased to $225.00 by Analysts at Stifel Nicolaus
www.americanbankingnews.com - May 7 at 2:58 PM |
| Idexx Laboratories' (IDXX) "Positive" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - May 7 at 2:57 PM |
 | Idexx Laboratories (IDXX) Q1 2018 Earnings Conference Call Transcript
www.fool.com - May 7 at 2:31 PM |
| BRIEF-Idexx Laboratories Reports Q1 Earnings Per Share $1.01
www.reuters.com - May 5 at 5:58 PM |
| Edited Transcript of IDXX earnings conference call or presentation 4-May-18 12:30pm GMT
finance.yahoo.com - May 5 at 5:58 PM |
| Idexx Laboratories (IDXX) Posts Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - May 4 at 8:33 PM |
| Idexx Laboratories (IDXX) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 4 at 10:14 AM |
| IDEXX Laboratories Inc Q1 Profit Climbs
www.nasdaq.com - May 4 at 8:07 AM |
| IDEXX Laboratories beats by $0.08, beats on revenue
seekingalpha.com - May 4 at 8:07 AM |
| IDEXX Laboratories Announces First Quarter Results
finance.yahoo.com - May 4 at 8:07 AM |
| IDEXX Labs Boosts 2018 EPS Outlook, But Backs Revenue View - Quick Facts
www.nasdaq.com - May 4 at 8:07 AM |
| IDEXX Labs Q1 top line up 16%; earnings up 30%; cash flow up 12%
seekingalpha.com - May 4 at 8:07 AM |
| Idexx: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:07 AM |
| IDEXX Laboratories (IDXX) Beats on Q1 Revenues, View Upbeat
finance.yahoo.com - May 4 at 8:07 AM |
| Idexx Laboratories (IDXX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 4 at 12:41 AM |
| Zacks: Brokerages Expect Idexx Laboratories (IDXX) Will Post Quarterly Sales of $526.18 Million
www.americanbankingnews.com - May 3 at 4:26 AM |
| Analysts Expect Idexx Laboratories (IDXX) to Announce $0.93 EPS
www.americanbankingnews.com - May 1 at 8:21 AM |
| Idexx Laboratories Reaches Analyst Target Price
www.nasdaq.com - April 29 at 8:10 AM |
| Idexx Laboratories (IDXX) Scheduled to Post Earnings on Friday
www.americanbankingnews.com - April 27 at 1:16 AM |
| Idexx Laboratories (IDXX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 26 at 1:42 PM |
| Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?
finance.yahoo.com - April 24 at 5:44 PM |
| Idexx Laboratories (IDXX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 24 at 12:16 PM |
| Q1 2018 EPS Estimates for Idexx Laboratories Boosted by Analyst (IDXX)
www.americanbankingnews.com - April 23 at 1:20 AM |
| Analysts Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $525.03 Million
www.americanbankingnews.com - April 16 at 4:00 AM |
| Reviewing IDEXX Laboratories (IDXX) & The Competition
www.americanbankingnews.com - April 15 at 7:18 PM |
| IDEXX Laboratories (IDXX) versus The Competition Financial Review
www.americanbankingnews.com - April 15 at 5:15 PM |
| IDEXX Laboratories (IDXX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 14 at 10:53 PM |
| $0.93 Earnings Per Share Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - April 14 at 7:41 AM |
 | Global Veterinary Molecular Diagnostics Market to Reach US$ 792.5 Mn by 2025, Says TMR
www.prnewswire.com - April 13 at 5:44 PM |
| IDEXX Laboratories (IDXX) & Its Peers Head-To-Head Contrast
www.americanbankingnews.com - April 13 at 8:53 AM |
| IDEXX Laboratories to Release 2018 First Quarter Financial Results
finance.yahoo.com - April 12 at 5:54 PM |
| Edited Transcript of IDXX presentation 6-Mar-17 3:25pm GMT
finance.yahoo.com - April 12 at 5:54 PM |
| Critical Comparison: IDEXX Laboratories (IDXX) & Its Peers
www.americanbankingnews.com - April 12 at 5:27 PM |
| Analyzing IDEXX Laboratories (IDXX) and BG Medicine (BGMD)
www.americanbankingnews.com - April 12 at 3:35 AM |
| IDEXX Laboratories (IDXX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 9 at 1:55 PM |
| IDEXX Laboratories (IDXX) Receives "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 5 at 9:36 PM |
| Top Reasons Why I Like Abaxis In 2018
seekingalpha.com - April 4 at 4:25 PM |
Idexx Laboratories (NASDAQ:IDXX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Idexx Laboratories (NASDAQ:IDXX) Income Statement, Balance Sheet and Cash Flow Statement
Idexx Laboratories (NASDAQ IDXX) Stock Chart for Monday, May, 21, 2018
Loading chart…
